Testing A New Experimental Drug To Raise Good Cholesterol Level

Testing A New Experimental Drug To Raise Good Cholesterol Level.


An speculative stupefy that raises HDL, or "good," cholesterol seems to have passed an introductory difficulty by proving tried and true in prelude trials. Although the trial was primarily designed to manner at safety, researchers scheduled to alms the finding Wednesday at the American Heart Association's annual union in Chicago also report that anacetrapib raised HDL cholesterol by 138 percent and edited LDL, HDL's destruction twin, almost in half mercury drug price of antibiotic. "We apophthegm very encouraging reductions in clinical events," said Dr Christopher Cannon, live father of the study, which also appears in the Nov 18, 2010 progeny of the New England Journal of Medicine.



A big retreat to affirm the results would take four to five years to accomplished so the drug is still years away from market, said Cannon, who is a cardiologist with Brigham and Women's Hospital in Boston. Other experts are intrigued by the findings, but note that the fact-finding is still in very ancient stages. "There are a lot of folk in the prevention/lipid scope that are simultaneously excited and leery," said Dr Howard Weintraub, clinical number one of the Center for the Prevention of Cardiovascular Disease at NYU Langone Medical Center in New York City.



Added Dr John C LaRosa, president of the State University of New York (SUNY) Downstate Medical Center in New York City: "It's very introductory but it's portentous because the behind analgesic out of the barrel of this sort was not a success. This looks be a better drug, but it's not through and through by any means. Don't have recourse to this to the bank".



LaRosa was referring to torcetrapib, which, liking for anacetrapib, belongs to the division of drugs known as cholesterol ester cart protein (CETP) inhibitors. A beamy pilot on torcetrapib was killed after investigators found an increased jeopardy of destruction and other cardiovascular outcomes. "I would be more disturbed about anacetrapib if I hadn't seen what happened to its cousin torcetrapib," Weintraub said. "Torcetrapib raised HDL astoundingly but that was in toto neutralized by the rise in cardiovascular events".